Description of Guardant Health Inc's Business Segments
Guardant Health Inc. is a leading precision oncology company that specializes in non-invasive genomic diagnostics and companion diagnostics for cancer patients. Its innovations are centered on blood-based genomic testing, providing crucial insights into cancer biology and helping to inform targeted treatments.
Segments, Products, and Services
1. Guardant360 Guardant360 is Guardant Healths flagship product, recognized for being a comprehensive liquid biopsy test. This test is pivotal in the realm of precision oncology as it provides an expansive genomic profile of solid tumors through a simple blood sample.
- Key Features: - Comprehensive Analysis: The Guardant360 test assesses more than 50 genes known to be associated with cancer, thereby identifying mutations that may influence the treatment pathway. - Clinical Application: The information gleaned from this test enables healthcare providers to better match patients with targeted therapies, immunotherapies, and relevant clinical trials. This aligns treatment options more closely with the specific genetic alterations in a patient’s cancer. - Reporting: Physicians receive detailed reports that highlight actionable insights and clinical significance of the identified mutations, which can significantly impact treatment decisions.
GuardantOmni Building on the framework laid by Guardant360, GuardantOmni offers a broader range of genomic analysis capable of detecting alterations across various solid tumors.
- Key Features: - Extensive Gene Coverage: This test covers over 500 genes, thereby providing a more extensive genomic profile by utilizing both circulating tumor DNA (ctDNA) and tumor DNA. - Insight into Resistance Mechanisms: GuardantOmni is particularly useful in identifying potential resistance mechanisms in tumors, thus helping in the adaptation of treatment strategies based on the evolving landscape of the disease. - Broader Tumor Applicability: This test is designed to be applicable across all solid tumor types, making it a versatile tool in clinical oncology.
LUNAR LUNAR is Guardant Healths research-use-only product focused on the early detection of cancer, exemplifying the company’s commitment to innovation and early intervention.
- Key Features: - Proprietary Technology: This liquid biopsy test employs advanced methodologies to detect ctDNA in the early stages of cancer, making it especially relevant for asymptomatic individuals. - Goal of Early Detection: By allowing for the detection of cancer at an earlier stage, LUNAR aims to enhance patient outcomes through timely intervention, which is crucial for improving long-term survival rates.
Companion Diagnostics In addition to their primary products, Guardant Health collaborates with pharmaceutical companies to create companion diagnostic tests. These tests are critical in identifying patients who are likely to benefit from specific therapies, thus facilitating personalized treatment approaches.
- Collaboration with Pharmaceuticals: The partnership with drug companies enables the development of tests that align with new therapeutic agents in the pipeline, thereby guiding optimal patient selection for clinical trials and treatment. - Patient Stratification: Companion diagnostics play a vital role in stratifying patient populations to ensure that therapies are administered to those most likely to respond, which can enhance clinical outcomes and optimize resource utilization.
Summary Guardant Health Inc. stands at the forefront of precision oncology with its innovative product suite that emphasizes non-invasive genomic diagnostics. Each segment—Guardant360, GuardantOmni, and LUNAR—serves a unique purpose, ranging from comprehensive tumor profiling to early detection of cancer. Coupled with companion diagnostics, Guardant Health provides essential tools that empower healthcare providers to make informed, data-guided treatment decisions, ultimately aimed at improving patient outcomes in the complex landscape of cancer treatment.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
126.59 %